prednisone has been researched along with Autosomal Recessive Emery-Dreifuss Muscular Dystrophy in 1 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dadgar, S | 1 |
Wang, Z | 1 |
Johnston, H | 1 |
Kesari, A | 1 |
Nagaraju, K | 1 |
Chen, YW | 1 |
Hill, DA | 1 |
Partridge, TA | 1 |
Giri, M | 1 |
Freishtat, RJ | 1 |
Nazarian, J | 1 |
Xuan, J | 1 |
Wang, Y | 1 |
Hoffman, EP | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)[NCT03439670] | Phase 2 | 121 participants (Actual) | Interventional | 2018-06-29 | Completed | ||
A Phase II Open-Label, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)[NCT05185622] | Phase 2 | 54 participants (Anticipated) | Interventional | 2022-03-21 | Recruiting | ||
A Phase II Pilot Trial of Vamorolone vs. Placebo for the Treatment of Becker Muscular Dystrophy[NCT05166109] | Phase 2 | 39 participants (Anticipated) | Interventional | 2022-07-07 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Vamorolone at 6.0mg/kg/day vs. placebo group in change from baseline to the Week 24 assessment (NCT03439670)
Timeframe: 24 weeks
Intervention | Rises/Seconds (Mean) |
---|---|
Treatment Group 1 | -.007 |
Treatment Group 2 | 0.054 |
1 other study available for prednisone and Autosomal Recessive Emery-Dreifuss Muscular Dystrophy
Article | Year |
---|---|
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |